Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT01708629
First received: September 21, 2012
Last updated: September 26, 2013
Last verified: September 2013
  Purpose

The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis.

A second purpose of this study is to assess the safety and efficacy brodalumab at two different doses compared with ustekinumab in participants with moderate to severe plaque psoriasis.

A third purpose of this study is to assess the safety and efficacy of 4 maintenance regimens of brodalumab.


Condition Intervention Phase
Moderate to Severe Plaque Psoriasis
Drug: 210 mg brodalumab
Drug: 140 mg brodalumab
Drug: ustekinumab
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3

Resource links provided by NLM:


Further study details as provided by Amgen:

Primary Outcome Measures:
  • Improvement in Psoriasis Area and Severity Index (PASI) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Efficacy of brodalumab in subjects with moderate to severe plaque psoriasis

  • Static Physician Global Assessment (sPGA) score [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Efficacy of brodalumab in subjects with moderate to severe plaque psoriasis


Secondary Outcome Measures:
  • Improvement in Psoriasis Area and Severity Index (PASI) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Efficacy of brodalumab in subjects with moderate to severe plaque psoriasis

  • Static Physician Global Assessment (sPGA) score [ Time Frame: 12 weeks and 52 weeks ] [ Designated as safety issue: No ]
    Efficacy of brodalumab in subjects with moderate to severe plaque psoriasis

  • Patient reported outcomes symptom score [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Subject-reported outcomes assessment

  • Subject incidence of adverse events [ Time Frame: 12 weeks and 5 years ] [ Designated as safety issue: Yes ]
    Safety profile of brodalumab

  • Subject incidence of adverse events of interest [ Time Frame: 12 weeks and 5 years ] [ Designated as safety issue: Yes ]
    Safety profile of brodalumab

  • Presence of anti-brodalumab antibodies [ Time Frame: 12 weeks and 5 years ] [ Designated as safety issue: Yes ]
    Safety profile of brodalumab


Enrollment: 1881
Study Start Date: September 2012
Estimated Study Completion Date: October 2018
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 210 mg brodalumab
Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
Drug: 210 mg brodalumab
210 mg brodalumab administered SC
Experimental: 140 mg brodalumab
Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
Drug: 140 mg brodalumab
140 mg brodalumab administered SC
Active Comparator: ustekinumab
Administered by subcutaneous (SC) injection per the labeled dosing regimen.
Drug: ustekinumab
45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
Placebo Comparator: Placebo
Administered by SC injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
Drug: 210 mg brodalumab
210 mg brodalumab administered SC
Drug: placebo
placebo administered SC

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has had stable moderate to severe plaque psoriasis for at least 6 months
  • Subject has involved body surface area (BSA) ≥ 10%, PASI ≥ 12, and sPGA ≥ 3 at screening and at baseline

Exclusion Criteria:

  • Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, or other skin conditions at (eg, eczema) that would interfere with study evaluations
  • Subject has known history of Crohn's disease
  • Subject has any other significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol
  • Subject has not stopped using certain psoriasis therapies as defined in the study protocol
  • Subject has previously used ustekinumab or any anti-IL-17 biologic therapy
  • Subject is pregnant or breastfeeding, or planning to become pregnant while enrolled in the study
  • Female subject is unwilling to use highly effective methods of birth control unless 2 years post-menopausal or surgically sterile
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01708629

  Hide Study Locations
Locations
United States, Alabama
Research Site
Birmingham, Alabama, United States, 35205
Research Site
Mobile, Alabama, United States, 36608
United States, Arizona
Research Site
Phoenix, Arizona, United States, 85023
United States, California
Research Site
Beverly Hills, California, United States, 90212
Research Site
Burbank, California, United States, 91505
Research Site
Encino, California, United States, 91436
Research Site
Freemont, California, United States, 94538
Research Site
Fullerton, California, United States, 92835
Research Site
Irvine, California, United States, 92614
Research Site
Los Angeles, California, United States, 90036
Research Site
Riverside, California, United States, 92505
Research Site
Sacramento, California, United States, 95819
Research Site
San Diego, California, United States, 92123
Research Site
San Diego, California, United States, 92103
Research Site
San Francisco, California, United States, 94118
United States, Colorado
Research Site
Denver, Colorado, United States, 80220
United States, Connecticut
Research Site
Farmington, Connecticut, United States, 06030
Research Site
Trumbull, Connecticut, United States, 06611
United States, Florida
Research Site
Boca Raton, Florida, United States, 33486
Research Site
Coral Gables, Florida, United States, 33134
Research Site
Hollywood, Florida, United States, 33021
Research Site
Jacksonville, Florida, United States, 32204
Research Site
Miami, Florida, United States, 33144
Research Site
Ocala, Florida, United States, 34471
Research Site
Tamarac, Florida, United States, 33321
United States, Georgia
Research Site
Alpharetta, Georgia, United States, 30022
Research Site
Atlanta, Georgia, United States, 30327
Research Site
Macon, Georgia, United States, 31217
United States, Idaho
Research Site
Boise, Idaho, United States, 83704
United States, Illinois
Research Site
Arlington Heights, Illinois, United States, 60005
Research Site
Champaign, Illinois, United States, 61820
Research Site
Maywood, Illinois, United States, 60153
Research Site
Normal, Illinois, United States, 61761
Research Site
Wheaton, Illinois, United States, 60189
United States, Indiana
Research Site
Indianapolis, Indiana, United States, 46256
Research Site
New Albany, Indiana, United States, 47150
United States, Kansas
Research Site
Overland Park, Kansas, United States, 66215
Research Site
Overland Park, Kansas, United States, 66202
United States, Kentucky
Research Site
Louisville, Kentucky, United States, 40217
Research Site
Owensboro, Kentucky, United States, 42303
United States, Massachusetts
Research Site
Worcester, Massachusetts, United States, 01605
United States, Michigan
Research Site
Ann Arbor, Michigan, United States, 48103
Research Site
Clarkston, Michigan, United States, 48346
Research Site
Clinton Township, Michigan, United States, 48038
United States, Nevada
Research Site
Henderson, Nevada, United States, 89074
Research Site
Las Vegas, Nevada, United States, 89144
United States, New Jersey
Research Site
East Windsor, New Jersey, United States, 08520
Research Site
Hoboken, New Jersey, United States, 07030
Research Site
Verona, New Jersey, United States, 07044
United States, New York
Research Site
Bronx, New York, United States, 10467
Research Site
New York, New York, United States, 10016
Research Site
Rochester, New York, United States, 14623
United States, North Carolina
Research Site
High Point, North Carolina, United States, 27262
United States, Ohio
Research Site
Cincinnati, Ohio, United States, 45249
Research Site
Cleveland, Ohio, United States, 44106
United States, Oregon
Research Site
Lake Oswego, Oregon, United States, 97035
Research Site
Portland, Oregon, United States, 97210
United States, Pennsylvania
Research Site
Exton, Pennsylvania, United States, 19341
United States, Rhode Island
Research Site
Johnston, Rhode Island, United States, 02919
United States, South Carolina
Research Site
Greer, South Carolina, United States, 29650
United States, Tennessee
Research Site
Bartlett, Tennessee, United States, 38134
Research Site
Nashville, Tennessee, United States, 37205
United States, Texas
Research Site
Bellaire, Texas, United States, 77401
Research Site
Dallas, Texas, United States, 75231
Research Site
Dallas, Texas, United States, 75230
Research Site
Houston, Texas, United States, 77030
Research Site
Houston, Texas, United States, 77082
Research Site
Houston, Texas, United States, 77004
Research Site
Webster, Texas, United States, 77598
United States, Utah
Research Site
Salt Lake City, Utah, United States, 84132
United States, Virginia
Research Site
Norfolk, Virginia, United States, 23507
Research Site
Richmond, Virginia, United States, 23294
United States, Washington
Research Site
Spokane, Washington, United States, 99204
United States, West Virginia
Research Site
Clarksburg, West Virginia, United States, 26301
Australia, New South Wales
Research Site
Camperdown, New South Wales, Australia, 2050
Research Site
Darlinghurst, New South Wales, Australia, 2010
Research Site
Kogarah, New South Wales, Australia, 2217
Research Site
St Leonards, New South Wales, Australia, 2065
Research Site
Sydney, New South Wales, Australia, 2000
Research Site
Westmead, New South Wales, Australia, 2145
Australia, South Australia
Research Site
Hectorville, South Australia, Australia, 5073
Australia, Western Australia
Research Site
Fremantle, Western Australia, Australia, 6160
Belgium
Research Site
Brugge, Belgium, 8000
Research Site
Brussels, Belgium, 1200
Research Site
Edegem, Belgium, 2650
Research Site
Gent, Belgium, 9000
Research Site
Leuven, Belgium, 3000
Research Site
Liege, Belgium, 4000
Research Site
Montigny-le-Tilleul, Belgium, 6110
Canada, Alberta
Research Site
Calgary, Alberta, Canada, T2G 1B1
Canada, British Columbia
Research Site
Vancouver, British Columbia, Canada, V5Z 4E8
Canada, Manitoba
Research Site
Winnipeg, Manitoba, Canada, R3C 1R4
Research Site
Winnipeg, Manitoba, Canada, R3C 0N2
Canada, Newfoundland and Labrador
Research Site
St. John's, Newfoundland and Labrador, Canada, A1A 5E8
Research Site
St. John's, Newfoundland and Labrador, Canada, A1A 4Y3
Canada, Nova Scotia
Research Site
Halifax, Nova Scotia, Canada, B3H 0A2
Canada, Ontario
Research Site
Barrie, Ontario, Canada, L4M 6L2
Research Site
Hamilton, Ontario, Canada, L8N 1V6
Research Site
Markham, Ontario, Canada, L3P 1A8
Research Site
Richmond Hill, Ontario, Canada, L4B 1A5
Research Site
Toronto, Ontario, Canada, M3H 5Y8
Research Site
Toronto, Ontario, Canada, M5S 3B4
Research Site
Toronto, Ontario, Canada, M8X 1Y9
Canada, Quebec
Research Site
Drummondville, Quebec, Canada, J2B 5L4
Research Site
Montreal, Quebec, Canada, H3Z 2S6
Research Site
Saint-Hyacinthe, Quebec, Canada, J2S 6L6
France
Research Site
Créteil Cedex, France, 94010
Research Site
Limoges, France, 87000
Research Site
Nice, France, 06200
Research Site
Poitiers, France, 86000
Research Site
Saint Priest en Jarez, France, 42270
Research Site
Toulouse Cedex 9, France, 31059
Research Site
Vandoeuvre les Nancy, France, 54511
Greece
Research Site
Athens, Greece, 16121
Research Site
Chaidari, Athens, Greece, 12462
Research Site
Ioannina, Greece, 45500
Research Site
Larissa, Greece, 41110
Research Site
Maroussi, Athens, Greece, 15123
Research Site
Thessaloniki, Greece, 54643
Research Site
Thessaloniki, Greece, 56429
Hungary
Research Site
Bekescsaba, Hungary, 5600
Research Site
Budapest, Hungary, 1085
Research Site
Gyula, Hungary, 5700
Research Site
Szeged, Hungary, 6720
Research Site
Szolnok, Hungary, 5000
Research Site
Szombathely, Hungary, 9700
Italy
Research Site
Bologna, Italy, 40138
Research Site
Genova, Italy, 16132
Research Site
Milano, Italy, 20122
Research Site
Milano, Italy, 48018
Research Site
Roma, Italy, 00168
Research Site
Roma (RM), Italy, 00133
Latvia
Research Site
Riga, Latvia, 1001
Research Site
Riga, Latvia, LV-1013
Research Site
Riga, Latvia, 1003
Research Site
Ventspils, Latvia, 3601
Poland
Research Site
Bialystok, Poland, 15-879
Research Site
Dabrowka Dopiewo, Poland, 62-069
Research Site
Gdansk, Poland, 80-952
Research Site
Iwonicz Zdroj, Poland, 38-440
Research Site
Katowice, Poland, 40-954
Research Site
Krakow, Poland, 30-510
Research Site
Kraków, Poland, 31-501
Research Site
Lodz, Poland, 90-242
Research Site
Lublin, Poland, 20-406
Research Site
Poznan, Poland, 60-539
Research Site
Stalowa-Wola, Poland, 37-450
Research Site
Swidnik, Poland, 21-040
Research Site
Warszawa, Poland, 01-192
Research Site
Warszawa, Poland, 02-201
Russian Federation
Research Site
Ekaterinburg, Russian Federation, 620076
Research Site
Moscow, Russian Federation, 107076
Research Site
Moscow, Russian Federation, 119991
Research Site
Moscow, Russian Federation, 121614
Research Site
Saint-Petersburg, Russian Federation, 194044
Research Site
Saratov, Russian Federation, 410026
Research Site
St. Petersburg, Russian Federation, 191015
Sponsors and Collaborators
Amgen
Investigators
Study Director: MD Amgen
  More Information

Additional Information:
No publications provided

Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT01708629     History of Changes
Other Study ID Numbers: 20120104
Study First Received: September 21, 2012
Last Updated: September 26, 2013
Health Authority: United States: Food and Drug Administration
Australia: Therapeutic Goods Association (TGA)
Belgium: Federal Agency for Medicines and Health Products, FAMHP
Canada: Health Canada
France: National Agency for Medicines and Health Products Safety (ANSM)
Greece: National Drug Organization (EOF)
Hungary: National Institute for Pharmacy
Italy: IRCCS Azienda Ospedaliera Universitaria San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro
Latvia: State Agency of Medicines
Poland: The Office for Registration of Medical Products, Medical Devices and Biocidal Products
Russia: Ministry of Healthcare and Social Development of the Russian Federation

Keywords provided by Amgen:
psoriasis, brodalumab, AMG 827

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases

ClinicalTrials.gov processed this record on August 21, 2014